ASH 2020 | CD58 aberrations correlate with poor response to axi-cel in LBCL
David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the findings of a study investigating tumor specific factors associated with inherent or acquired resistance to axicabtagene ciloleucel (axi-cel) CAR-T cell therapy in large B cell lymphoma (LBCL). The study analyzed tumor DNA, from blood or tumor biopsies, in patients treated with axi-cel. The study found that mutations in, and loss of expression of, LFA-3 (CD58) correlated with lack of response or poor response longevity to axi-cel treatment. This was shown to be due to subsequent loss of CD2 signaling, which has a costimulatory role in T-cells. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
